Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vildagliptin twice daily versus sitagliptin once daily for oxidative stress and inflammation in type 2 diabetes
2010-019346-11Phase 4Active
- Sponsor
- Azienda Ospedaliera Universitaria Luigi Vanvitelli
- Start
- Dec 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in type 2 diabetes mellitus (T2DM) comparing Vildagliptin twice daily plus metformin with Sitagliptin once daily plus metformin (2 arms). Primary endpoints: Nitrotyrosine reduction and Proinflammatory cytokine reduction. Started Dec 2011; status: active.
02
Drugs
vildagliptinsitagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2010-019346-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-019346-11.